Symptomatic Relief for Overactive Bladder (OAB)

Бетмига is commonly used for the long-term, symptomatic management of Overactive Bladder Syndrome (OAB) in adult patients. It is applied to ease symptom clusters that may become intense or disruptive, including urinary urgency, urinary frequency, and urge urinary incontinence. This medication supports the patient by easing the overall symptom load and may contribute to managing symptoms that interfere with functional stability, which generally contributes to improved day-to-day comfort and may assist with easing the need to void during the night.

---

Support for Complex and Specialized Indications

This medicine is considered relevant when supportive symptom management is appropriate, particularly for patients whose OAB symptoms have not been adequately managed by previous first-line treatments. It may be part of symptomatic management used in combination with other classes of bladder medicines to assist with maintaining functional stability.

Indications for its use also extend to a specialized area: addressing Neurogenic Detrusor Overactivity (NDO) in pediatric patients in the approved age range. This condition is a therapeutic focus when symptoms are associated with heightened physiological activity that requires symptomatic management.

Quick Fact	Relief for Symptom
Primary Use	OAB Symptoms (Urgency, Frequency, Incontinence)
Specialized Use	Neurogenic Detrusor Overactivity (NDO)
Symptom Focus	Chronic, disruptive symptom patterns
Context	Monotherapy or Combination Therapy

---

Regulatory References

1. NIH DailyMed official information

Eligibility Map: Who Can and Cannot Use Бетмига

The eligibility profile for using this medicine (Mirabegron) is strictly defined by government regulatory documents based on age, underlying conditions, and physiological status.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label):	Adults (aged 18 years and older) with OAB. Pediatric patients 3 years for Neurogenic Detrusor Overactivity (NDO).
Populations for whom use is contraindicated:	Patients with known hypersensitivity or severe uncontrolled hypertension (systolic BP 180 mmHg and/or diastolic BP 110 mmHg).
Age-related eligibility rules:	Approved for adults and children 3 years for NDO. Use for OAB in children is not established.
Condition-specific eligibility rules:	Patients with End-Stage Renal Disease (ESRD) or severe hepatic impairment (Child-Pugh Class C) are not recommended for use.
Pregnancy and lactation eligibility status:	Not recommended during pregnancy or for nursing/breastfeeding mothers.
Eligibility-related restrictions:	Maximum dose of 25 mg once daily applies to patients with severe renal impairment or moderate hepatic impairment. Caution is advised in patients with clinically significant Bladder Outlet Obstruction (BOO).

---

Eligibility Classifications (High-Level)

Classification	Official Regulatory Wording (Examples)
Eligibility severity classification:	Contraindicated, Not Recommended, Use with Caution, Use Not Established.
Eligibility-context constraints:	Constrained by specific blood pressure thresholds, organ function severity (e.g., eGFR < 15 mL/min/1.73 m^2), and concurrent strong CYP3A inhibitor use.

---

Connection to the overall eligibility profile

Regulatory documents establish the official parameters for use by clearly defining absolute prohibitions (contraindications), setting organ impairment limits (prohibiting or restricting use based on liver or kidney function severity), and specifying approved age groups and conditions (approving adult OAB and pediatric NDO but not pediatric OAB). The eligibility rules provide a mandated, non-negotiable framework for use.

Interactions with other medicines and products

The official regulatory profile for Mirabegron (the active substance in Бетмига) is defined by its effect on key metabolic enzymes and drug transporters. Mirabegron is a moderate inhibitor of the CYP2D6 enzyme and a weak inhibitor of the P-glycoprotein (P-gp) transporter.

This metabolic influence dictates several documented interaction constraints. Co-administration with CYP2D6 substrates (such as Thioridazine, Flecainide, and Propafenone) results in an increase in the systemic exposure of the co-administered drug. Regulatory documents require appropriate monitoring and possible dose adjustments for these substrates, particularly those with a narrow therapeutic index. Similarly, the P-gp inhibition by Mirabegron increases the exposure of P-gp substrates like Digoxin, mandating that the lowest initial dose be prescribed and serum concentrations be monitored.

Population-Specific and Contraindicated Combinations:

A combination restriction exists with Strong CYP3A Inhibitors (e.g., Ketoconazole). This co-administration is not recommended in patients with Severe Renal Impairment or Moderate Hepatic Impairment. For patients with milder degrees of renal or hepatic impairment who require a Strong CYP3A Inhibitor, official labeling restricts the Mirabegron dose to 25 mg once daily. Furthermore, caution is required when co-administering Mirabegron with Muscarinic Antagonist OAB agents due to a documented additive risk of urinary retention. The prolonged-release tablet formulation is labeled to be taken with or without food.

How Бетмига Works

---

Selective beta3-Adrenoceptor Agonism

The primary action of the active ingredient, Mirabegron, is highly specific activation (agonism) of the beta3-Adrenoceptors (beta3-AR), which are concentrated in the smooth muscle of the bladder wall (the detrusor muscle). This interaction operates within the autonomic nervous system to selectively facilitate smooth muscle relaxation, a process distinct from mechanisms that block muscarinic receptors.

cAMP Signaling Cascade and Muscle Relaxation

Activation of the beta3-AR triggers a crucial intracellular pathway by stimulating adenylate cyclase, which rapidly increases the level of the second messenger cyclic adenosine monophosphate ( cAMP) within the muscle cells. This cascade ultimately leads to a reduction in available intracellular calcium, which results in detrusor smooth muscle relaxation and a decrease in muscle tone.

Augmentation of Bladder Storage Function

The resulting physiological effect of detrusor relaxation facilitates the bladder's distension and accommodation of fluid, increasing its compliance and functional storage capacity during the urine filling phase. This mechanism modifies the biomechanical state of the bladder's storage physiology.

How to Use Mirabegron (Бетмига)

Mirabegron is administered orally and is available as prolonged-release tablets (25 mg and 50 mg strengths) and prolonged-release granules for oral suspension. The primary administration pattern is once daily for adults. The medicine is taken as a long-term therapy for the symptomatic management of Overactive Bladder.

---

Standard Administration and Dosing

The standard adult starting dose is 25 mg once daily. The dosage may be increased to a maximum of 50 mg once daily based on response, typically after a minimum of four to eight weeks. Tablets must be swallowed whole with water and must not be chewed, divided, or crushed, as this would compromise the controlled-release mechanism. Adult patients taking the tablets may do so with or without food.

---

Population-Specific Use and Restrictions

Patient Group	Maximum Daily Dose Limit	Context
Severe Renal Impairment	25 mg	Adults with eGFR 15 to 29 mL/min/1.73 m^2
Moderate Hepatic Impairment	25 mg	Adults classified as Child-Pugh Class B
Pediatric NDO	Weight-based dosing	Uses tablets (over 35 kg) or oral suspension (under 35 kg)

In cases where a dose is missed, it should be taken as soon as it is remembered if less than 12 hours have passed since the scheduled time. If more than 12 hours have passed, the missed dose must be skipped, and the regular schedule should be resumed the following day.

Research evidence / Overview of studies for Бетмига

Evidence for Use in Overactive Bladder (OAB) Symptoms

The clinical evaluation for mirabegron in adults with OAB symptoms was conducted in short-term, large randomized controlled trials (RCTs). These studies was evaluated in research exploring how symptoms change over time, comparing the observed patterns in patient groups who received mirabegron against groups receiving a placebo (an inactive substance) over typically 12 weeks. Researchers monitored outcomes related to functional imbalance and physical discomfort, focusing on objective changes in symptoms such as the daily frequency of urination and the number of urge urinary incontinence episodes.

These short-term RCTs studies monitored objective diary entries. Specifically, findings reported how the mean number of incontinence and micturition episodes evolved over the 12-week study period. Studies also monitored functional biomarkers, reporting how the volume of urine voided per micturition evolved in the observed populations.

---

Evidence for Use in Neurogenic Detrusor Overactivity (NDO)

The research examining mirabegron for Neurogenic Detrusor Overactivity (NDO) has focused on a specialized pediatric population, specifically children and adolescents. Studies was evaluated in conditions marked by functional limitations and utilized open-label designs. This approach utilized a different research design than the blinded RCTs.

These trials was evaluated in conditions marked by functional limitations and focused on objective functional measurements derived from urodynamic testing. The studies monitored primary outcomes related to the bladder's physiological strain, such as changes in objective functional measures derived from urodynamic testing, such as bladder capacity.

---

Long-Term Studies and Follow-up

Research has also explored outcomes beyond the initial 12-week trial period through open-label extension studies and real-world observational settings evaluating daily-life functioning. These studies monitored patients for periods extending up to a year and sometimes longer. The purpose of this research was to gather evidence regarding treatment maintenance patterns of use and adherence.

Long-term effects are not fully established through the highest-quality evidence. The follow-up durations were limited in the most rigorous studies, and the evidence quality varies across studies, as observational data differs from that of blinded trials.

---

What is Still Uncertain About Bettmiga Research

A significant uncertainty is the lack of long-term (multi-year), large-scale, placebo-controlled data, meaning the long-term effects are not fully established. For the NDO indication, the primary research relied on open-label study designs, meaning the certainty remains low compared to research supported by blinded RCTs. Furthermore, available data do not fully address the role of mirabegron compared to newer or combination therapies in the published scientific literature. The research does not determine whether an individual will respond similarly to the group patterns observed in the clinical trials, as findings describe group averages, not personal outcomes.

Key Studies & References

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials

Common questions about Бетмига (FAQ)

Q: Can I take Бетмига if I also take a blood pressure medication?

Official regulatory documents advise caution regarding co-administering this medicine with blood pressure medications, as Mirabegron can potentially increase blood pressure. The official labeling does not prohibit co-administration with all such drugs, but it recommends that blood pressure be monitored periodically during treatment.

Q: Is it necessary to have certain tests done before starting Бетмига?

The official label sets limits for use based on severe uncontrolled high blood pressure and end-stage kidney or liver disease. Therefore, medical assessment is typically conducted to ensure the patient's health status, such as blood pressure and organ function, falls outside of the contraindication limits before starting treatment.

Q: Why might a patient switch from another OAB drug to Бетмига?

Regulatory documents describe this medicine as a beta3-adrenoceptor agonist, which represents a different pharmacological mechanism than older medications used for OAB. This distinction establishes it as an alternative treatment option for managing overactive bladder symptoms.

Q: Is it considered safe to take Бетмига with a common antidepressant?

Mirabegron is described in official documents as a moderate inhibitor of the CYP2D6 enzyme, which is involved in processing many common antidepressants. Because of this interaction, official information suggests caution and monitoring when taking both types of medication, and a possible dose adjustment of the co-administered drug may be considered.

Q: What is the official classification of this drug (e.g., controlled substance)?

According to official regulatory status, this drug is classified as a prescription-only medicine. It is not listed as a controlled substance in major international drug schedules.

Q: What is the difference between an extended-release and an immediate-release drug form?

The prolonged-release (or extended-release) formulation is engineered to release the active substance slowly and steadily over a longer period. This differs from an immediate-release form, which is designed to release the medicine into the body all at once for quick absorption.

Q: Is the medication designed to treat nighttime urination (nocturia) specifically?

The medication is officially indicated for the symptomatic treatment of overactive bladder (OAB) syndrome in general. Nocturia (nighttime urination) is one of the key symptoms of OAB that was specifically monitored in the clinical studies that evaluated the medicine.

Q: What does 'contraindication' mean in the context of Бетмига?

In official drug documents, a 'contraindication' describes a specific health condition or circumstance where using the medicine is absolutely not recommended because it may cause harm. For this medicine, an example is severe uncontrolled hypertension.

Q: If I have mild hypertension, can I still take Bettmiga?

Official regulatory documents only prohibit use for patients with severe uncontrolled hypertension (high blood pressure above specific thresholds). If the condition is mild or controlled, the drug is not explicitly prohibited, but periodic monitoring of blood pressure is officially recommended during treatment.

Q: How long does it usually take to notice an effect after starting Бетмига?

Clinical studies often assess the medicine's therapeutic effect on overactive bladder symptoms after four to eight weeks of starting treatment or following a dose adjustment. Symptom change timelines are typically evaluated over this duration.

Q: Are there any common foods or drinks that should be avoided when taking Бетмига?

According to the official product information, the tablets may be taken with or without food. There are no specific food or drink restrictions noted in the regulatory documents that are necessary to avoid while taking this medication.

Q: Does Бетмига interact with common pain relievers like ibuprofen?

Official documents specify warnings for drugs that affect the CYP2D6 enzyme and P-glycoprotein transporter. There are no specific warnings listed regarding interaction with common over-the-counter pain relievers like ibuprofen or acetaminophen in the regulatory documents.

Q: Does Бетмига cause weight gain, according to research?

Weight gain is not listed as a common, uncommon, or rare adverse reaction in the official regulatory safety profile for this medicine.

Q: Can Бетмига affect sleep patterns?

Changes to sleep patterns, such as insomnia or drowsiness, are not listed as common, uncommon, or rare side effects in the official regulatory safety profile.

Q: What happens if I decide to stop taking Бетмига suddenly?

The regulatory information does not list any symptoms of physical dependence or withdrawal after stopping the medication suddenly. The general expectation is that the underlying overactive bladder symptoms for which the patient is being treated may return.

Q: Does the official product information mention anything about alcohol and Бетмига?

The official product information does not contain specific instructions or warnings regarding the consumption of alcohol while taking this medication.

Q: Is a metallic taste in the mouth a known, but rare, side effect of Бетмига?

Metallic taste is not listed as a common, uncommon, or rare adverse reaction in the official regulatory safety profile. Side effects are officially grouped by their likelihood of occurrence.

Q: Is it possible to take Бетмига if I have glaucoma?

According to the official regulatory documents, glaucoma is not listed as a contraindication or a specific warning for this medication.

Q: Does taking Бетмига affect my ability to drive or operate machinery?

Official documents do not include a specific warning stating that this medicine affects the ability to drive or operate machinery.

Q: Does Бетмига work immediately after the first dose?

Official pharmacokinetic data describes the time needed for the active substance to reach its highest level in the bloodstream. However, regulatory documents do not state that the medicine provides immediate symptom relief after the first dose.

Q: Is it normal to feel a dry mouth while taking this medication?

Dry mouth is not listed as a common, uncommon, or rare adverse reaction in the official regulatory safety profile. This medicine belongs to a different pharmacological class than those traditionally associated with dry mouth.

Q: Is it possible to develop a tolerance to the effects of Бетмига over time?

The regulatory research overview does not contain a specific statement regarding the development of tolerance (a loss of treatment effect) over time. Studies have explored treatment maintenance patterns of use.

Q: Does the package insert mention any specific time of day for taking Бетмига?

The official administration instructions state that the medicine should be taken once daily. However, the regulatory documents do not mandate a specific time of day for administration, such as morning or evening.

Q: Are there specific instructions for what to do if I take too much Бетмига?

Regulatory documents advise that in the event of an overdose (taking too much of the medicine), treatment should be supportive and focused on symptoms. If an overdose is suspected, it is advised that emergency services or a poison control center be contacted immediately for guidance.

Q: Are there any known interactions between Бетмига and herbal supplements?

Official documents do not list specific herbal supplements that interact with the medicine. Regulatory documents advise caution when the medicine is used with any substance that affects the CYP3A enzyme or the P-glycoprotein transporter, as this could potentially change the level of the medicine in the body.

Q: Is it possible to take Bettmiga if I have asthma?

Asthma is not listed as a contraindication or a specific warning in the official regulatory documents for this medication.

How to Store and Dispose of Betmiga (Mirabegron): Official Regulatory Information

The storage and disposal instructions for Betmiga are provided by regulatory agencies to ensure product stability and public safety.

Item	Official Regulatory Statement
Labeled storage temperature	Tablets must be stored below 30 C in a cool, dry place. The reconstituted suspension must be kept at 20 C to 25 C (controlled room temperature).
Protection requirements	Store tablets in the original container/blister pack to protect them from heat and dampness.
Stability after reconstitution	The prepared oral suspension must be discarded after 28 days from the date of mixing, as documented in the label.
Child-protection storage	The medicine must be kept out of the sight and reach of children at all times.
Official disposal rules	Unused or expired tablets must be returned to a pharmacist or drug take-back program. Do not dispose of the medicine in household waste or flush it down the toilet or sink.

Regulatory documents define storage constraints by setting a maximum temperature and requiring the product to remain in its original pack. Disposal is strictly managed through the pharmaceutical waste system to ensure environmental protection.